Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Y-2 sublingual tablet in healthy volunteers (SALVAGE)
NCT03495206Phase 1Unknown
- Sponsor
- Yantai Yinuoyi Biomedical Technology
- Start
- Oct 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of edaravone dexborneol in ischemic stroke and intracranial hemorrhage (ICH), sponsored by Yantai Yinuoyi Biomedical Technology. Primary endpoint: Number of participants who experience treatment-related adverse events (AEs) and serious adverse events (SAEs) at 36 hours. Status: unknown.
02
Drugs
edaravone dexborneol
03
Conditions
ischemic strokeintracranial hemorrhage (ICH)
Beyond the preview
Go deeper on NCT03495206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03495206.